Pliant Therapeutics, Inc.
PLRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.14 | 1.02 | -0.78 | -0.04 |
| FCF Yield | -19.99% | -11.03% | -11.87% | -15.99% |
| EV / EBITDA | -3.44 | -6.39 | -6.68 | -4.59 |
| Quality | ||||
| ROIC | -62.69% | -37.97% | -38.36% | -46.86% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.74 | 0.72 | 0.77 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -40.69% | -38.59% | -48.99% |
| Free Cash Flow Growth | -35.87% | -21.67% | -24.54% | -99.46% |
| Safety | ||||
| Net Debt / EBITDA | 0.05 | 0.33 | 0.15 | 0.46 |
| Interest Coverage | -75.52 | -145.34 | -160.81 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,023.72 | 692.34 | -38.18 | -219.59 |